TWST — Twist Bioscience Corporation

Is TWST overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Neutral As of August 19, 2026

Twist Bioscience Corporation (TWST) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Diagnostics & Research) last closed at $116.10. The rating moved from Oversold to Neutral on August 19, 2026.

AI analysis

Twist Bioscience sits at the intersection of growing demand for synthetic DNA and the broader biologics/CRO supply chain. Its proprietary, high-throughput platform gives it a technical and scalability edge that can capture incremental share as mRNA, personalized oncology, and biologics programs expand. Near-term macro and sentiment tailwinds for growth names support upside, while execution (manufacturing scale, margin improvement) and customer funding cycles are the primary constraints. Key catalysts include quarterly revenue/margin beats, new commercial partnerships, and continued adoption by large biotech customers; downside scenarios center on weaker biotech funding, increased competition, or the need for dilutive financing.

Key factors

  • Exposure to biologics/CRO/CDMO demand as DNA synthesis and library services support accelerated biologics and mRNA development
  • Proprietary high-throughput silicon-based DNA synthesis platform provides technical differentiation and scalability versus traditional providers
  • Recent market risk-on rotation into growth/AI names increases appetite for growth biotech suppliers and strengthens near-term sentiment
  • Potential revenue upside from expanding commercial partnerships, new product introductions, and increased adoption in synthetic biology and diagnostics
  • Valuation reflects growth expectations; improving gross margins and operating leverage are achievable as volumes scale
  • Neutral SEC 8-K with no material negative disclosures supports stable near-term information flow

Risks

  • Cyclicality and concentration of biotechnology customers—funding slowdowns at customers could compress demand quickly
  • Intense competition from established life-science suppliers and emerging alternative synthesis technologies
  • Ongoing cash burn and need for financing if free cash flow remains negative; dilution risk from capital raises
  • Execution risk scaling manufacturing while maintaining high quality and yield
  • Pricing pressure as customers negotiate volume discounts or switch suppliers
  • Regulatory, supply-chain, or geopolitical disruptions that could impede operations or deliveries
  • Market sentiment reversal (risk-off) or disappointing earnings could produce sharp multiple contraction

See today's live rating, score and targets

Members see the live hourly rating for TWST — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.